Material Safety Data Sheet
Revision: 10/18/2004
Hazard information is provided for compliance with both the UK Chemicals
(Hazard Information and Packaging) (CHIP) Regulations and the US Hazard
Communication Standard (HCS)
IDENTIFICATION OF THE PRODUCT NAME: PRODUCT CODE: EEC NUMBER:
SUBSTANCE/PREPARATION Methotrexate, Ultrapure 18970 200-413-8
AND COMPANY
SUPPLIER: Emergency Contact:
USB Corporation, 26111 Miles Road, Cleveland, Ohio 44128 Phone: (216) 765-5000 Chemtrec (800) 424-9300
Please visit our website at www.usbweb.com for contact information on USB Outside USA & Canada 703 527 3887
product distributors within your area.
COMPOSITION/
HAZARDOUS COMPONENTS HAZARD CAS NO. %WT TLV CHIP R & S Phrases
Methotrexate 59-05-2 ~100% 鈥? R:25 Toxic if swallowed.
R:46 May cause heritable damage.
R:61 May cause harm to the unborn child.
S:22 Do not breathe dust.
S:24/25 Avoid contact with skin and eyes.
S:36/37/39 Wear suitable protective
clothing, gloves and eye/face protection.
S:45 In case of accident or if you feel
unwell, seek medical advice immediately
(show label where possible).
S:53 Avoid exposure-obtain special
instructions before use.
HAZARDS IDENTIFICATION CHIP
Toxic
HCS
Toxic, Category 3 Carcinogen
FIRST-AID MEASURES EYES: Flush with water for 15 minutes. Seek medical advice if irritation persists.
SKIN: Flush with water, then wash thoroughly with soap and water. Remove contaminated clothing and wash
before reuse. Seek medical attention if irritation persists.
INHALATION: Remove the victim from exposure and move to fresh air. If breathing is difficult, give oxygen. If
not breathing, give artificial respiration. Keep victim quiet and warm. Seek immediate medical attention.
INGESTION: Drink water and seek immediate medical attention. Avoid alcoholic beverages. Never give
anything by mouth to an unconscious person. DO NOT induce vomiting.
FIRE-FIGHTING INFORMATION Use media suitable to extinguish the supporting or surrounding fire. Wear NIOSH (or equivalent) approved self
contained breathing apparatus. For small fires only: use carbon dioxide, dry powder or foam. This material
decomposes at temperatures above 185掳C emitting toxic fumes of carbon and nitrogen oxides.
Flash Point = No data available.
ACCIDENTAL RELEASE MEASURES Wear appropriate personal protective equipment and clothing including lab coat, safety goggles, gloves and NIOSH-
approved respirator. Collect in a manner that does not create dust and place in a suitable waste container. Avoid
contact of material with skin or eyes. Use adequate ventilation.
HANDLING AND STORAGE Wear appropriate personal protective equipment and clothing including lab coat, safety goggles, gloves and NIOSH-
approved respirator. Avoid contact of material with skin or eyes. Use adequate ventilation. Light sensitive.
Hygroscopic. Store at +4掳C away from incompatible materials.
PERSONAL PROTECTION Wear appropriate personal protective equipment and clothing including lab coat, safety goggles, gloves and NIOSH-
approved respirator. A qualified industrial hygienist should evaluate the need for respiratory protection. Use
respiratory protection approved by NIOSH (or equivalent) and appropriate to the hazard. Avoid contact of material
with skin or eyes. Mechanical ventilation or local exhaust as needed to control exposure to dust, vapors or mists.
Access to a safety shower and eye-wash. Wash thoroughly after handling.
PHYSICAL AND CHEMICAL Appearance: Bright yellow, orange crystalline powder Boiling Point: No data available
PROPERTIES Vapor Pressure: No data available Vapor Density: No data available
Solubility (Water): Insoluble Specific Gravity: No data available
Percent Volatile: No data available Evaporation Rate: No data available
Chemical Formula: C20-H22-N8-O5 Melting Point: 185-204掳C
MSDS information may be continued on back of page.
STABILITY AND REACTIVITY Product is stable. Hygroscopic. May decompose on exposure to light. Protect from light and moisture. Hazardous
decomposition products include carbon and nitrogen oxides. Incompatible with strong oxidizing agents and strong
acids. Hazardous polymerization will not occur.
TOXICOLOGICAL INFORMATION EFFECTS OF OVEREXPOSURE:
EYES: Contact may cause irritation.
SKIN: May be toxic if absorbed through the skin and possibly lead to symptoms described under ingestion.
Contact may cause irritation and dermatitis.
INHALATION: May be toxic by inhalation and possibly lead to symptoms described under ingestion. May
cause irritation to mucous membranes and upper respiratory tract.
INGESTION: Toxic if swallowed. Chronic ingestion or excessive dosage may cause leukopenia, anemia,
thrombocytopenia, nausea, vomiting, diarrhea, dizziness, headache, fever, ulcerative stomatitis, necrosis of
the interdental papillae, hepatitis, pneumonitis, mucositis, renal failure, dark blood stool, blurred vision,
decreased resistance to infection and hair loss. Methotrexate is both teratogenic and a Category 2
mutagen causing DNA damage. Chronic exposure may cause mylelosuppresion and liver and kidney
damage. Pregnant women should avoid contact with Methotrexate due to the possibility of fetal
deformation or fetal death. May cause harm to the unborn child. May cause heritable genetic damage.
NOTE TO PHYSICIAN: Calcium leucovorin is a potent agent for neutralizing the immediate effects of
methotrexate on the blood-forming system. In general, when overexposure is known or suspected,
calcium leucovorin should be administered as soon after exposure as possible. See the latest edition of the
Physicians Desk Reference for recommended doses and routes of administration. Methotrexate blood levels
should be monitored and the calcium leucovorin dose adjusted accordingly.
TARGET ORGAN(S): Blood, Bone Marrow, Liver, G.I. System, Kidneys, Immune System and Lungs.
ADDITIONAL INFORMATION:
Methotrexate is a cytotoxic agent specifically designed to kill cells by preventing division or inhibiting cell growth.
The cell damage from cytotoxic agents is accumulative with a build-up of effects on continuing exposure
(irrespective of whether the drug itself is accumulating in the body).
Reproductive effects, irritation, mutation, tumorigenic and toxicity data listed in RTECS under MA1225000.
Only select RTECS information is provided here. Please see actual RTECS entry for complete information.
TDLo Oral Human (man ) = 4256 ug/kg/2.7Y-I (1982). Oral Rat LD50 = 135 mg/kg (1982). Toxic effects may
included fibrosis, focal (pneumoconiosis), respiratory obstruction and aplastic anemia.
Reproductive: Effects on embryo or fetus included fetotoxicity (except death, e.g. stunted fetus) (1968) and
fetal death (1975).
Specific developmental abnormalities - musculoskeletal, craniofacial, central nervous
system, body wall, eye/ear and cytological (1968).
Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number
of implants) (1968) and abortion (1973).
Reproductive - Paternal effects - spermatogenesis (inc. genetic material, sperm morphology,
motility, and count) (1969). Maternal effects - ogenesis (1968).
Carcinogenicity data: NCI Carcinogenesis Studies (ipr): no evidence: mouse, rat.
IARC Cancer Review: Animal - Inadequate Evidence (1972).
Human - Inadequate Evidence (1972).
Group 3 - Agent is not classifiable as to its carcinogenicity to humans (1979).
Tumorigenic data: Carcinogenic by RTECS criteria (1967).
Equivocal tumorigenic agent by RTECS criteria (1959).
Definition(s): IARC = International Agency for Research on Cancer
NCI = National Cancer Institute.
RTECS = Registry of Toxic Effects of Chemical Substances.
ECOLOGICAL INFORMATION No information available.
DISPOSAL CONSIDERATIONS Dispose of material in accordance with applicable local, state, and federal regulations.
TRANSPORTATION INFORMATION US DOT / IATA: Toxic solid, organic, n.o.s. (Methotrexate), class 6.1, UN 2811, PG III, Label: Toxic.
REGULATORY INFORMATION RCRA - No applicable information.
SARA 302 - This material does not have an RQ or TPQ.
SARA 313 - This material is not reportable under 313.
EPA TSCA Section 8(b) - Chemical Inventory.
Exposure Limits - Not established.
California Proposition 65 - This product is or contains chemical(s) known to the State of California to cause
developmental toxicity.
This data sheet is based upon information believed to be reliable. The Company makes no statement or warranty as to the accuracy or completeness of the
information contained herein which is offered for your consideration, investigation and verification. Any use of the information contained in this data sheet
must be determined by the user to be in accordance with appropriate applicable regulations.
|